Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by retiredcopon May 27, 2020 9:54am
91 Views
Post# 31077359

RE:RE:RE:Antibody tests for Covid-19 wrong half the time, CDC says

RE:RE:RE:Antibody tests for Covid-19 wrong half the time, CDC saysGreat t9o see you posting again Mr Wilson .. I think 99.9 is going to be the new norm for test to be excepted going forward. I also think that 10 companies manufacturing will not be able to keep up the supply. This is a world crisis so we have to take into account the estimated 7.57 BILLION people on this rock. Now take into account the number of tesdts needed, not only right now to give an indication of how many people have developed anitbodies for covid and will this test be almost like a minimum requirement in many situations before a person can travel, we just dont know how this will unfold. As we get into the vaccine stage, the test will be very importna tin seeing if the vaccination is working, will it need boosters. Alot of us are focusing on FDA approval, but if you check further you will see that FGDA or federal approval is not required right now for tests or  treatment. For example , In Canada each province can decide what they want to use and they can select their own treatments and tests. Its what ever they want to pay for. Thats why I mentioned a while back that we can start locally, the western provinces and spreading from there. With PMN, in the back of our minds we are always looking at the option that someone bigger out there is interested in taking over the science .. " Ray, if you build it they will come"         
Bullboard Posts